Business Wire

Xsolla Expands Payments in the Americas to Boost Conversions With Pay by Bank, Affirm, and Recurring Billing via Mercado Pago

14.8.2025 21:00:00 CEST | Business Wire | Press release

Share

New Support For Local Payment Methods Helps Developers Align With How Players Across The Americas Prefer To Pay

Xsolla, a global commerce company helping developers launch, grow and monetize their games, announces today a major expansion of its localized payments offering across North and South America today. With new support for Pay by Bank and Affirm in the United States, Affirm in Canada, and recurring billing via Mercado Pago in Brazil, developers and publishers using Xsolla Pay Station can now unlock new revenue streams, reduce friction, and better connect with players through regionally trusted payment methods.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250814368955/en/

(Graphic: Xsolla)

The Americas remain one of the largest and most diverse gaming regions, with a combined market value of approximately USD 100 billion. However, while opportunities are vast, consumer expectations regarding payments vary dramatically by country. Players in the U.S. increasingly seek fast, secure alternatives to credit cards; Canadian gamers are embracing flexible payment options; and in Brazil, a major economy, recurring billing through trusted platforms like Mercado Pago is essential for long-term retention.

To meet these regional needs, Xsolla Pay Station now supports:

  • Pay by Bank in the U.S. – Faster, secure, bank-direct payments are rapidly gaining traction among players and retailers.

  • Affirm in the U.S. (live) and Canada – A flexible Buy Now, Pay Later option that increases accessibility and basket size.

  • Mercado Pago in Brazil (enhanced) – Now supporting recurring billing to enable live service models and subscription-based monetization.

Key benefits of the Payments in the Americas expansion include:

  • Localized Payment Solutions: Offer trusted regional payment methods, including Pay by Bank, Affirm, and Mercado Pago, ensuring players can pay in their preferred manner in every market. Reflects the growing consumer shift toward convenient, secure, and flexible payment methods.

  • Frictionless Checkout Experiences: Mobile-first, secure payment flows help reduce abandonment and improve conversion rates.

  • Wider Reach Across North & South America: Localized support in the U.S., Canada, and Brazil opens access to millions of players, backed by the adoption of Pay by Bank (35M+ U.S. users engaging with open banking), Affirm (22M+ U.S. shoppers as of 2024), and Mercado Pago (64M monthly active users in Brazil, integrated across 145,000+ live sites), reflecting the growing demand for convenient, secure, and flexible payment experiences.

  • Flexible Monetization Models: To fit your revenue strategy, offer one-time payments, Buy Now Pay Later (BNPL) options, and subscriptions.

  • Increased Player Trust and Loyalty: Familiar payment methods foster confidence and encourage players to return.

“We’re making it easier for developers to reach players in North and South America with payment experiences that feel native to each market,” said Chris Hewish, President at Xsolla. “By enabling Pay by Bank, Affirm, and recurring billing with Mercado Pago, we’re helping our partners connect with more players, increase conversions, and offer real flexibility in how they monetize across the Americas.”

To learn more or enable these regional payment methods for your game, get started: https://publisher.xsolla.com/

For a complete list of enhancements and developer tools, visit: xsolla.pro/rws25paymentsinamerica

About Xsolla

Xsolla is a global commerce company with robust tools and services to help developers solve the inherent challenges of the video game industry. From indie to AAA, companies partner with Xsolla to help them fund, distribute, market, and monetize their games. Grounded in the belief in the future of video games, Xsolla is resolute in the mission to bring opportunities together, and continually make new resources available to creators. Headquartered and incorporated in Los Angeles, California, Xsolla operates as the merchant of record and has helped over 1,500+ game developers to reach more players and grow their businesses around the world. With more paths to profits and ways to win, developers have all the things needed to enjoy the game.

For more information, visit xsolla.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20250814368955/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye